LCTX (Lineage Cell Therapeutics) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

What is Lineage Cell Therapeutics LT-Debt-to-Total-Asset?

Lineage Cell Therapeutics LCTX +3.85% 79 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates LCTX with a GF Score™ of 79/100 and a GF Value™ of $1.33 (Fairly Valued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lineage Cell Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Lineage Cell Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.01) to Mar. 2026 (0.01). It may suggest that Lineage Cell Therapeutics is progressively becoming more dependent on debt to grow their business.

Lineage Cell Therapeutics (AMEX:LCTX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lineage Cell Therapeutics LT-Debt-to-Total-Asset Related Terms

Lineage Cell Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Lineage Cell Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lineage Cell Therapeutics LT-Debt-to-Total-Asset Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.02

0.01

Lineage Cell Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.02	0.01	0.01

79GF Score

Lineage Cell Therapeutics Inc LCTX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lineage Cell Therapeutics LT-Debt-to-Total-Asset Calculation

Lineage Cell Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	1.566	/	112.584
	=	0.01

Lineage Cell Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	1.529	/	109.533
	=	0.01

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

Lineage Cell Therapeutics (LCTX) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lineage Cell Therapeutics and its competitors.

Is Lineage Cell Therapeutics' LT-Debt-to-Total-Asset too high?

Lineage Cell Therapeutics' current LT-Debt-to-Total-Asset is 0.01. Overall, Lineage Cell Therapeutics has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Lineage Cell Therapeutics' LT-Debt-to-Total-Asset compare to NWBO and ABEO?

Lineage Cell Therapeutics' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Lineage Cell Therapeutics and its competitors. Lineage Cell Therapeutics's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lineage Cell Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.35 — trading 1.5% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Lineage Cell Therapeutics' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be overvalued. The current stock price of $1.35 is trading 1.5% above its estimated GF Value™ of $1.33. GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.

Key valuation signals for LCTX:

LT-Debt-to-Total-Asset: 0.01
GF Value™: $1.33 vs. price of $1.35 (1.5% above fair value)
GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies NWBO ABEO VRXA SLNCF GALT PALI IMRX IRD VSTM MGNX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges LCTX:Israel BT3:Germany

Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

79GF Score

Get the complete analysis for LCTX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.35

Price

$1.33

GF Value

View LCTX Analysis

See LT-Debt-to-Total-Asset data for all stocks →